人表皮生长因子受体阳性晚期非小细胞肺癌的治疗进展

Research progress of treatment of HER2 positive non-small cell lung cancer

晚期非小细胞肺癌预后较差,靶向治疗已给晚期非小细胞肺癌的治疗带来根本性的变革,改善了驱动基因突变相关患者的生存。人表皮生长因子受体(HER2)在非小细胞肺癌驱动基因中属于少见突变,往往提示更差的预后。针对HER2阳性肺癌的相应靶向药物治疗已取得一定疗效,部分新药仍在临床试验中,免疫检查点抑制剂的应用也为相关治疗提供了更多选择,但目前仍无标准治疗方案,现有治疗药物主要包括抗体偶联药物,包括HER2靶点的表皮生长因子受体抑制剂,近年来免疫检查点抑制剂也取得了一定疗效,但上述治疗方法均未能获得广泛的良好疗效。本文就非小细胞肺癌中HER2的致病背景、对预后的影响,现有治疗药物的疗效、新药的进展以及治疗前优势人群的选择进行综述。

Targeted therapy has played a very important role in the treatment of advanced non-small cell lung cancer and has significantly improved the survival rate of patients.The incidence of mutation of ErbB2 receptor tyrosine kinase 2(HER2)in non-small cell lung cancer NSCLC is fewer,suggesting poor prognosis of patients.Several targeted HER2 drugs have obtained certain curative effects,however,some clinical trials are still ongoing,including antibody-drug conjugates.In recent years the clinical use of immune checkpoint inhibitors has provided more choices in the treatment.This article will review the background of HER2 positive NSCLC,and its effects on the prognosis of patients,treatment drugs,clinical advances and selection of domination groups.